Agilent Technologies Inc
0HAV.L
$141.46 2.00%
Exchange: LSE | Sector: Healthcare | Industry: Medical Pharmaceuticals
Q3 2024
Published: Aug 30, 2024

Earnings Highlights

  • Revenue of $1.58B down 5.6% year-over-year
  • EPS of $0.97 increased by 155.3% from previous year
  • Gross margin of 54.2%
  • Net income of 282.00M
  • "N/A" - N/A

Agilent Technologies Inc (0HAV.L) QQ3 2024 Results Analysis: Resilient Life Sciences Instrumentation Demand, Margin Expansion, and Strong Free Cash Flow

Executive Summary

Agilent Technologies reported QQ3 2024 results with solid profitability and robust free cash flow, despite a year-over-year revenue decline. Revenue totaled USD 1.578 billion, down 5.6% year over year, while gross profit reached USD 855 million for a gross margin of 54.18%. Operating income was USD 333 million (operating margin 21.10%), yielding net income of USD 282 million and EPS of USD 0.97. Notably, gross margins expanded meaningfully on a YoY basis, even as the top line declined, signaling favorable mix and disciplined cost control. QoQ, revenue increased modestly by 0.32%, but some margin pressure persisted as operating expenses remained elevated, resulting in a sequential dip in operating and net income. Free cash flow was strong at USD 360 million, supporting a cash balance of USD 1.78 billion and a net debt position of USD 1.15 billion after meaningful stock repurchases. The quarter contributed to a trailing four-quarter revenue run rate of roughly USD 6.50 billion, with a net income trajectory that improved meaningfully in the period (TTM EPS around USD 4.84 if one aggregates the quarterly results). The company continued to deploy capital toward shareholder value, evidenced by USD 585 million of common stock repurchases in QQ3 2024 and a modest dividend, highlighting a disciplined capital-return strategy while maintaining liquidity to fund R&D and strategic initiatives. Overall, Agilent remains well-positioned in a favorable long-term growth environment driven by Life Sciences research, Diagnostics, Genomics, and ongoing demand for high-value analytical instrumentation. The key near-term questions relate to the pace of lab capex cycles, FX sensitivity, and the durability of margin gains as the company manages through a modest revenue secular headwind and ongoing investment in software-enabled services and product innovation.

Key Performance Indicators

Revenue

1.58B
QoQ: 0.32% | YoY:-5.62%

Gross Profit

855.00M
54.18% margin
QoQ: -0.12% | YoY:29.94%

Operating Income

333.00M
QoQ: -8.26% | YoY:150.38%

Net Income

282.00M
QoQ: -8.44% | YoY:154.05%

EPS

0.97
QoQ: -7.62% | YoY:155.26%

Revenue Trend

Margin Analysis

Key Insights

Revenue: USD 1,578,000,000; YoY change: -5.62%; QoQ change: +0.32% Gross Profit: USD 855,000,000; YoY change: +29.94%; QoQ change: -0.12%; Gross Margin: 54.18% Operating Income: USD 333,000,000; YoY change: +150.38%; QoQ change: -8.26%; Operating Margin: 21.10% Net Income: USD 282,000,000; YoY change: +154.05%; QoQ change: -8.44%; Net Margin: 17.87% EPS: USD 0.97; YoY change: +155.26%; QoQ change: -7.62% EBITDA: USD 428,000,000; EBITDA Margin: 27.12% Operating Cash Flow: USD 452,000,000; Free Ca...

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q3 2025 1,738.00 1.18 +10.1% View
Q2 2025 1,668.00 0.75 +6.0% View
Q1 2025 1,681.00 1.11 +1.4% View
Q4 2024 1,701.00 1.22 +0.8% View
Q3 2024 1,578.00 0.97 -5.6% View